SCHEMBL1974573

SCHEMBL1974573

OCCCN1CCCNCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 8/20 0.70
HRH3 Q9Y5N1 3/20 0.43
HRH2 P25021 1/20 0.43
HRH1 P35367 1/20 0.43
CHRM2 P08172 2/20 0.43
CHRM1 P11229 2/20 0.43
MEN1 O00255 1/20 0.43
ADRA2C P18825 1/20 0.43
CCR2 P41597 1/20 0.43
CXCL12 P48061 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SIGMAR1 Q99720 3/20 0.42
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM3 P20309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20667031 0.96 CXCR4 (0.78) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL22711079 0.96 CXCR4 (0.63) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL12003 0.91 CXCR4 (0.56) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL11443013 0.91 CXCR4 (0.56) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL29943537 0.89 CXCR4 (0.54) CXCR4HRH3HRH2HRH1CHRM2
Hydrochloric Acid SCHEMBL6955567 0.89 CXCR4 (0.54) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL8714265 0.89 CXCR4 (0.59) CXCR4HRH3HRH2HRH1CHRM2
Piperazine SCHEMBL28092893 0.89 CXCR4 (0.59) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL969503 0.87 CXCR4 (0.63) CXCR4HRH3HRH2HRH1CHRM2
SCHEMBL12958912 0.87 CXCR4 (0.63) CXCR4HRH3HRH2HRH1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110294972-A A kind of ink 深圳TCL工业研究院有限公司 2019-10-01 CN claimed
US-4751298-A Production of 1-(3-hydroxy-propyl)-1,4-diazepane and 1,4-bis(3,4,5-trimethoxy-benzoyloxy)-propyl-diazepane derivatives thereof DEGUSSA AKTIENGESELLSCHAFT (DE) 1988-06-14 US claimed
EP-0152598-B1 Cyanomethyl-(2-cyano-ethyl)-(3-hydroxy-propyl)-amine and its use for the production of 1-(3-hydroxy-propyl)-1,4-diazepan and 1,4-bis-[3-(3,4,5-trimethoxy-benzoyloxy)-propyl]-diazepan Degussa Aktiengesellschaft (DE) 1988-04-20 EP claimed
EP-0152598-A1 Cyanomethyl-(2-cyano-ethyl)-(3-hydroxy-propyl)-amine and its use for the production of 1-(3-hydroxy-propyl)-1,4-diazepan and 1,4-bis-[3-(3,4,5-trimethoxy-benzoyloxy)-propyl]-diazepan Degussa Aktiengesellschaft (DE) 1985-08-28 EP claimed
WO-2023196930-A2 NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES PURDUE RESEARCH FOUNDATION (US) 2023-10-12 WO disclosed
CN-116535365-A Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-08-04 CN disclosed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US disclosed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US disclosed
CN-115768773-A Macrocyclic diamine derivatives as ENT inhibitors for the treatment of cancer and combinations thereof with adenosine receptor antagonists ITEOS比利时公司 2023-03-07 CN disclosed
EP-4132933-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-02-15 EP disclosed
EP-3828164-A1 NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME Protech Co., Ltd. (KR) 2021-06-02 EP disclosed
CN-110294972-A A kind of ink 深圳TCL工业研究院有限公司 2019-10-01 CN disclosed
US-4751298-A Production of 1-(3-hydroxy-propyl)-1,4-diazepane and 1,4-bis(3,4,5-trimethoxy-benzoyloxy)-propyl-diazepane derivatives thereof DEGUSSA AKTIENGESELLSCHAFT (DE) 1988-06-14 US disclosed
EP-0152598-B1 Cyanomethyl-(2-cyano-ethyl)-(3-hydroxy-propyl)-amine and its use for the production of 1-(3-hydroxy-propyl)-1,4-diazepan and 1,4-bis-[3-(3,4,5-trimethoxy-benzoyloxy)-propyl]-diazepan Degussa Aktiengesellschaft (DE) 1988-04-20 EP disclosed
EP-0152598-B1 Cyanomethyl-(2-cyano-ethyl)-(3-hydroxy-propyl)-amine and its use for the production of 1-(3-hydroxy-propyl)-1,4-diazepan and 1,4-bis-[3-(3,4,5-trimethoxy-benzoyloxy)-propyl]-diazepan Degussa Aktiengesellschaft (DE) 1988-04-20 EP disclosed
EP-0152598-A1 Cyanomethyl-(2-cyano-ethyl)-(3-hydroxy-propyl)-amine and its use for the production of 1-(3-hydroxy-propyl)-1,4-diazepan and 1,4-bis-[3-(3,4,5-trimethoxy-benzoyloxy)-propyl]-diazepan Degussa Aktiengesellschaft (DE) 1985-08-28 EP disclosed
EP-0152598-A1 Cyanomethyl-(2-cyano-ethyl)-(3-hydroxy-propyl)-amine and its use for the production of 1-(3-hydroxy-propyl)-1,4-diazepan and 1,4-bis-[3-(3,4,5-trimethoxy-benzoyloxy)-propyl]-diazepan Degussa Aktiengesellschaft (DE) 1985-08-28 EP disclosed
US-4169144-A Trimethoxyphenyl esters of homopiperazine-n-monoalkanol as vasodilators HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1979-09-25 US disclosed
US-4068069-A Novel piperazine- and homopiperazine- monoalkanol esters and a process of production thereof HOKURIKU PHARMACEUTICAL CO., LTD. (JA) 1978-01-10 US disclosed
US-3980643-A ANALGESICS, CORONARY VASODILATORS, ANTICONVULSANTS, BLOOD PRESSURE DECREASING HOKURIKU PHARMACEUTICAL CO., LTD. (JA) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 CXCR4 449/4885HRH3 1183/4885HRH2 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.